Literature DB >> 18369321

Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.

A Delluc-Clavières1, C Le Bec, L Van den Berghe, C Conte, V Allo, O Danos, A-C Prats.   

Abstract

IRESs (internal ribosome entry sites) are RNA elements behaving as translational enhancers in conditions of global translation blockade. IRESs are also useful in biotechnological applications as they allow expression of several genes from a single mRNA. Up to now, most IRES-containing vectors use the IRES from encephalomyocarditis virus (EMCV), highly active in transiently transfected cells but long and not flexible in its positioning relative to the gene of interest. In contrast, several IRESs identified in cellular mRNAs are short and flexible and may therefore be advantageous in gene transfer vectors such as those derived from the adeno-associated virus (AAV), where the size of the transgene expression cassette is limited. Here, we have tested bicistronic AAV-derived vectors expressing two luciferase genes separated by the EMCV- or fibroblast growth factor 1 (FGF-1) IRES. We demonstrate that the AAV vector with the FGF-1 IRES, when administrated into the mouse muscle, leads to efficient expression of both transgenes with a stable stoechiometry, for at least 120 days. Interestingly, the bicistronic mRNA containing the FGF-1 IRES leads to transgene expression 10 times superior to that observed with EMCV, in vivo. AAV vectors featuring the FGF-1 IRES may thus be advantageous for gene therapy approaches in skeletal muscle involving coexpression of genes of interest.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18369321     DOI: 10.1038/gt.2008.49

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  Comparison of red-shifted firefly luciferase Ppy RE9 and conventional Luc2 as bioluminescence imaging reporter genes for in vivo imaging of stem cells.

Authors:  Yajie Liang; Piotr Walczak; Jeff W M Bulte
Journal:  J Biomed Opt       Date:  2012-01       Impact factor: 3.170

Review 2.  Internal ribosome entry site-based vectors for combined gene therapy.

Authors:  Edith Renaud-Gabardos; Fransky Hantelys; Florent Morfoisse; Xavier Chaufour; Barbara Garmy-Susini; Anne-Catherine Prats
Journal:  World J Exp Med       Date:  2015-02-20

3.  Differential bicistronic gene translation mediated by the internal ribosome entry site element of encephalomyocarditis virus.

Authors:  Chia-Rui Shen; Ya-Shan Chen; Yih-Shiou Hwang; Hsi-Jien Chen; Chao-Lin Liu
Journal:  Biomed J       Date:  2020-06-24       Impact factor: 7.892

4.  Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism.

Authors:  Caroline Conte; Nadera Ainaoui; Aurélie Delluc-Clavières; Marie P Khoury; Rania Azar; Françoise Pujol; Yvan Martineau; Stéphane Pyronnet; Anne-Catherine Prats
Journal:  Nucleic Acids Res       Date:  2009-06-26       Impact factor: 16.971

5.  IRES-based vector coexpressing FGF2 and Cyr61 provides synergistic and safe therapeutics of lower limb ischemia.

Authors:  Audrey Rayssac; Charles Neveu; Mélanie Pucelle; Loïc Van den Berghe; Leonel Prado-Lourenco; Jean-François Arnal; Xavier Chaufour; Anne-Catherine Prats
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

6.  Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

Authors:  Edith Renaud-Gabardos; Florence Tatin; Fransky Hantelys; Benoît Lebas; Denis Calise; Oksana Kunduzova; Bernard Masri; Françoise Pujol; Pierre Sicard; Philippe Valet; Jérôme Roncalli; Xavier Chaufour; Barbara Garmy-Susini; Angelo Parini; Anne-Catherine Prats
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

7.  FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha.

Authors:  Caroline Conte; Elodie Riant; Céline Toutain; Françoise Pujol; Jean-François Arnal; Françoise Lenfant; Anne-Catherine Prats
Journal:  PLoS One       Date:  2008-08-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.